AstraZeneca Halts Key Lung Cancer Trial of Volrustomig After Missed Efficacy Goals

An update from AstraZeneca ( (GB:AZN) ) is now available.

AstraZeneca has halted its Phase III eVOLVE-Lung02 trial evaluating volrustomig plus chemotherapy as a first-line treatment for metastatic non-small cell lung cancer patients whose tumours express PD-L1 below 50%, after an independent data monitoring committee found the regimen was unlikely to meet primary endpoints for progression-free and overall survival in PD-L1 negative patients. The decision marks a setback for the company’s dual checkpoint inhibitor strategy in lung cancer but does not raise new safety concerns, and AstraZeneca plans to apply lessons from the trial while continuing other late-stage studies of volrustomig in cervical cancer, head and neck squamous cell carcinoma and mesothelioma, underscoring its ongoing commitment to next-generation immuno-oncology approaches despite the trial’s failure.

AstraZeneca will work with investigators to ensure continuity of care and appropriate follow up for patients enrolled in eVOLVE-Lung02, which included 895 participants across 25 countries. The company maintains that its diversified immuno-oncology pipeline, including bispecific antibodies and novel combination regimens, remains central to its strategy of addressing high unmet needs in cancer and sustaining its competitive position in the rapidly evolving oncology market.